Your compass for disease incidence and prevalence
Confidently navigate the ebb and flow of infectious diseases in your community – and beyond – with QIAsphere Insights. With data from your own QIAstat-Dx instruments and de-identified data from instruments around the world, track everything from pathogen diversity, to rates of co-detection, to Ct value measures. With QIAsphere Insights, the power of clinical epidemiology is in your hands.
What does QIAsphere Insights offer?
How can QIAsphere Insights support my work?
Pathogen diversity
Track the full scope of disease-causing pathogens* that exist in your community and see how their prevalence changes over time.
*Pathogen diversity is limited to the targets present on the QIAstat-Dx panels.
Positivity rates
See how positivity rates vary from week to week, month to month and year to year so you can react to outbreaks early and plan ahead for seasonal spikes in illness.
Ct values
View the median and mean Ct value measurements for different pathogens over time, and track how these measures relate to the number of positive cases.
Co-detections over time
View the top 5 most frequent pathogen co-detections over time, as well as a full breakdown of co-detections between every pathogen on a given QIAstat-Dx panel.
Global perspective
Scale up your insights – view epidemiology data for your institute and your entire geographic region. And with hundreds of QIAstat-Dx instruments connected to QIAsphere globally, you can even see aggregated, fully anonymized data from around the world.
Data shown corresponds to RSV obtained using the QIAstat-Dx Respiratory SARS-CoV-2 Panel from Nov 2022 – March 2023.
Customized .xls reports
If you’re looking for a way to expedite your epidemiology reporting, this is it. From your Insights dashboard, select only the data you want to see. Then quickly and easily export and download a full, customized report of your data in .xls format.
Useful findings from the Insights dashboard
Low-plex doesn’t cut it for respiratory infections
Our Insights dashboard shows that if you only test your patients for a few viral respiratory pathogens (Influenza A, Influenza B, RSV and SARS-CoV-2), you could be missing a huge proportion of positive cases.
A tale of two (types of) pathogens
The Centers for Disease Control and Prevention estimates that up to 50% of all outpatient antibiotic use may be unnecessary or inappropriate in selection, dose and duration (https://www.cdc.gov/antibiotic-use/data/outpatient-prescribing/index.html).
This rings true with results from our Insights dashboard for respiratory infections. In 2022, bacteria accounted for a very small percentage of positive detections, with viruses making up the vast majority.
More to explore
Data is aggregated from QIAsphere-connected QIAstat-Dx instruments only. Not all QIAstat-Dx instruments are connected to QIAsphere.
Access to the QIAsphere Insights dashboard requires a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.
Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor.
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner